Tech Company Financing Transactions
XOMA Corporation Funding Round
Blue Owl Capital invested in a $140 million capital raise for XOMA Corporation. The round was announced on 12/19/2023.
Transaction Overview
Company Name
Announced On
12/19/2023
Transaction Type
Venture Equity
Amount
$140,000,000
Round
Undisclosed
Investors
Blue Owl Capital (Lead Investor)
Proceeds Purpose
Proceeds expected to be used for stock repurchases and additional royalty and milestone acquisitions
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2200 Powell Street Suite 310
Emeryville, CA 94608
USA
Emeryville, CA 94608
USA
Phone
Website
Email Address
Overview
XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Financial Officer
Tom Burns
President
Owen Hughes
Browse more venture capital transactions:
Prev: 12/19/2023: Atavistik Bio venture capital transaction
Next: 12/19/2023: Unnatural Products venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on funding rounds that are announced publicly. All VC database entries on this site are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs